MoneyWorks4Me

FIIs cut stake in Biocon during Q3

09 Jan 2015 Evaluate

Foreign institutional investors (FIIs) have decreased their holdings in Biocon by over 200 basis points to 10.62% at the end of the third quarter from 13.05% in the second quarter ended September 30, 2014. The Foreign investors have sold 48.6 lakh shares representing 2.43% stake of Biocon during the recently concluded quarter.

On the other hand, domestic institutional investors’ (DIIs’) shareholding in the company has increased by 65 basis points to 7.60% from 6.95% in past three months.

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

397.25 -4.75 (-1.18%)
04-Sep-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.00
Dr. Reddys Labs. 1154.00
Cipla 1385.00
Lupin 2111.00
Zydus Lifesciences 1121.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: